Navigation Links
Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip
Date:6/12/2011

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biochip Markets: Microarrays and Lab-on-a-Chip

http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html

INTRODUCTION 

STUDY GOALS AND OBJECTIVES

BCC's goal for this study was to determine the status of current and emerging biochip technologies and products, and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We were particularly interested in characterizing the biochip markets for single nucleotide polymorphisms (SNPs), epigenetics, array comparative genome hybridization (aCGH), microRNA (miRNA), proteomics microarray, and lab-on-a-chip (LOAC) markets, which will provide substantial future growth opportunities for biochips. A particular focus of this study is the market for biochip-based diagnostics products. 

Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biochip technologies and the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

Biology is following a path that is reminiscent of the early electronics industry: a miniaturization and large-scale integration process that will revolutionize life-science research, drug discovery and development, medical diagnostics and biotechnology. The ongoing miniaturization and large-scale integration process is encompassed in devices known as biochips, including microarrays and LOAC microfluidic devices. Biochips represent a diverse group of nanotechnologies that can be expected to exert a significant impact in life-science research, diagnostics, and medicine.

DNA microarrays are already an established technology generating substantial revenue derived from gene expression, SNP analysis and gene resequencing. Several biochip-based diagnostics have been launched in the past few years, including some that have been approved by the FDA for in vitro diagnostic (IVD) applications. We foresee significant market growth in biochips as diagnostics. Protein microarrays are gaining prominence in the marketplace, while future, emerging array technologies, including tissue/cell and glycomics arrays, are increasing in importance. LOAC devices are also making rapid progress in important pharmaceutical and diagnostics market segments. 

BCC previously examined the biochip industry in 2007. Given the rapidly advancing bio- and nanotechnologies associated with this business, and the changing industry dynamics, it is timely to reexamine the biochips business. 

INTENDED AUDIENCE 

We have compiled a study of critical biochip technologies that will be important in the four major end-user segments. We present the biochip technologies and growth driving forces, product types, key market applications, companies, and alliances, future market potential and product sales forecasts for the period 2009 through 2014. We project the future use of microarray and LOAC products for the key end-use segments: research tools, drug discovery and development, diagnostics, next-generation sequencing, biodefense, food testing, and forensics. 

This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life-sciences tools, biodefense, medical devices, polymers, glass, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs, manufacturers of microarrays and LOAC devices, antibodies, restriction enzymes or primers, bioinformatics developers, and cancer researchers and clinicians.

SCOPE OF REPORT 

The study scope includes the major biochip technologies that are likely to become commercialized within the next 5 years. Each technology is analyzed to determine its market status, impact on future market segments, and forecast growth from 2009 through 2014. Technology issues and market driving forces are discussed. Influencing factors including large-scale integration, microfluidics, nanotechnology, large-scale biochip, genomic and proteomic research initiatives, cancer diagnostic and treatment trends, and drug discovery and development needs are discussed.

BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug discovery and development, diagnostics, next-generation DNA sequencing, biodefense, food safety, and forensics. 

Based on our analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2009 through 2014.

BCC examines biochip companies and industry alliances, and the impact of large-scale biochip-related projects on the market growth. We also examine patent strategies within the industry. A total of 143 companies are profiled. 

METHODOLOGY

Both primary and secondary research methodologies were used in this market study. For research tools and drug discovery and development, the study presents a forecast from 2009 through 2014 for each of the important products and technologies. For DNA microarrays, the study forecasts market size by application and analysis type. For diagnostics, the report forecasts from 2009 through 2014 the demand for biochips by chip type and by indication, as well as cancer biochips by type and application. This study forecasts from 2009 through 2014 the market for LOAC devices by end-use market and by application. The geographical markets are forecast for each biochip type. 

INFORMATION SOURCES

BCC surveyed life-science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, microarray and LOAC companies, and leading microarray research institutions. We also spoke with users of in vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.

ANALYST CREDENTIALS

The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.

THIS REPORT:

The total market for biochips was $2.4 billion in 2008 which increased to $2.6 billion in 2009. This is expected to grow at compound annual growth rate (CAGR) of 17.7% to reach $5.9 billion by 2014

The DNA microarrays market was nearly $1.2 billion in 2008; this further increased to $1.3 billion in 2009, this projected to reach $2.7 billion in 2014, for a 5-year CAGR of 15.2%.

Sales in the LOAC market amounted to $755 million in 2008 which increased to $817 million in 2009. This is projected to increase to $2.1 billion in 2014, for a 5-year CAGR of 20.9%.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, 2007-2014 ($ MILLIONS) 6

SUMMARY (CONTINUED) 7

Chapter-3: OVERVIEW

INTRODUCTION 8

INTRODUCTION (CONTINUED) 9

TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 10

FIGURE 1 EVOLUTION OF BIOCHIPS 10

INTRODUCTION (CONTINUED) 11

BIOCHIP TYPES 12

FIGURE 2 CLASSIFICATION OF BIOCHIPS 12

TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 13

BIOCHIP TYPES (CONTINUED) 14

TABLE 3 BIOCHIP NOMENCLATURE 15

BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT 16

TABLE 4 SCOPE OF THIS REPORT 16

WHAT IS NEW IN THIS REPORT 16

MARKET POTENTIAL OF BIOCHIPS 17

TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 18

TABLE 6 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 18

DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 19

TABLE 7 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 20

DRIVING FORCES FOR … (CONTINUED) 21

BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES 22

TABLE 8 MULTIDISCIPLINARY FIELD OF BIOCHIPS 22

LIFE CYCLE STATUS OF BIOCHIP PRODUCTS 23

TABLE 9 LIFE CYCLE STATUS OF BIOCHIP TYPES 23

COMMERCIAL STATUS OF BIOCHIPS 24

MICROARRAYS 24

LOAC 25

THE BIOCHIP INDUSTRY 25

TABLE 10 BIOCHIP INDUSTRY KEY COMPETITORS 25

THE BIOCHIP INDUSTRY (CONTINUED) 26

Chapter-4: MICROARRAY TECHNOLOGIES

INTRODUCTION 27

THE NANOSCALE WORLD 27

TABLE 11 THE NANOSCALE WORLD 27

TABLE 12 MICROARRAY TYPES 28

TABLE 13 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 28

The Nanoscale World (Continued) 29

DNA MICROARRAY TECHNOLOGIES 30

INTRODUCTION 30

FIGURE 3 MICROARRAY FEATURE DENSITY 30

FIGURE 4 MICROARRAY RESOLUTION 31

TABLE 14 MICROARRAY GENOME CONTENT 31

TABLE 15 DNA MICROARRAY PLATFORM FEATURES 32

TABLE 16 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33

TABLE 16 (CONTINUED) 34

Introduction (Continued) 35

STEPS IN THE DNA MICROARRAY EXPERIMENT 36

DNA MICROARRAY APPLICATIONS 36

TABLE 17 DNA MICROARRAY APPLICATIONS 37

Gene Expression Profiling 38

TABLE 18 PROBES FOR GENE EXPRESSION DNA MICROARRAYS 38

Gene Expression Profiling (Continued) 39

TABLE 19 EXAMPLE APPLICATIONS OF GENE EXPRESSION PROFILING 40

FIGURE 5 GENETIC ANALYSIS TECHNOLOGY COMPETITIVE SPACE 41

TABLE 20 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 42

FIGURE 6 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1 43

FIGURE 7 COMPETITIVE SPACE FOR GENE EXPRESSION ANALYSIS 44

FIGURE 8 APPLICATIONS SPACE WITH INTENSE TECHNOLOGY COMPETITION 45

Gene Expression Profiling (Continued) 46

TABLE 21 PLATFORMS FOR HIGH-THROUGHPUT QUANTITATIVE GENE EXPRESSION ANALYSIS 47

TABLE 22 GENE EXPRESSION PLATFORMS OF TWO LEADING DNA ARRAY MANUFACTURERS 47

TABLE 22 (CONTINUED) 48

TABLE 23 PROBE SENSITIVITY AND SPECIFICITY 48

Gene Expression Profiling (Continued) 49

SNP Analysis 50

FIGURE 9 SNP ANALYSIS PLATFORMS 51

Epigenetic Analysis 52

FIGURE 10 EPIGENOMICS WITHIN THE MOLECULAR BIOLOGY PARADIGM 53

DNA Methylation 53

FIGURE 11 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 54

Histones 54

FIGURE 12 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC 55

DNA Methylation and Histone Analysis Workflow 56

FIGURE 13 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS 57

DNA Methylation Microarrays 57

ChIP-on-Chip 58

TABLE 24 CHIP ASSAYS 59

TABLE 25 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 60

TABLE 26 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS 61

Cytogenetic Analysis 61

TABLE 27 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 62

FIGURE 14 COMPETITIVE SPACE FOR CNV ANALYSIS 63

Cytogenetic Analysis (Continued) 64

TABLE 28 CGH MICROARRAY PROBE PLATFORMS 65

TABLE 29 CGH MICROARRAY TRENDS 66

Cytogenetic Analysis (Continued) 67

TABLE 30 FUTURE TECHNOLOGY NEEDS FOR CGH MICROARRAYS 68

miRNA Analysis 69

TABLE 31 WORKFLOW FOR AN MIRNA EXPERIMENT 70

TABLE 32 TECHNICAL CHALLENGES FOR MIRNAS 71

ARRAYS ON BEADS 72

TABLE 33 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS 72

CATALOG AND CUSTOM DNA MICROARRAYS 72

SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS 73

TOXICOGENOMICS 74

DNA SEQUENCING 75

FIGURE 15 COMPARISON OF SANGER WITH UHTS DNA SEQUENCING TECHNOLOGIES 76

TABLE 34 SMS TECHNOLOGY 77

TABLE 35 COMPARISON OF SELECTED DNA SEQUENCING PLATFORMS 78

FIGURE 16 COMPETITIVE SPACE FOR HIGH-THROUGHPUT GENOMIC ANALYSIS 79

TABLE 36 BIOCHIP CONTENT IN NHGRI GRANTEES FOR NEXT-GENERATION DNA SEQUENCING, 2005 80

TABLE 36 (CONTINUED) 81

TABLE 37 NEXT-GENERATION DNA SEQUENCING COMPANIES 82

RESEQUENCING APPROACHES IN DIAGNOSTICS 82

DNA MICROARRAY MANUFACTURING 83

FIGURE 17 DNA MICROARRAY MANUFACTURING TECHNOLOGIES 83

DNA Microarray Manufacturing (Continued) 84

TABLE 38 DNA MICROARRAY PROBE DENSITY TRENDS, FEATURES PER CHIP, 1996–2009 85

DNA MICROARRAY TECHNOLOGY TRENDS 85

DNA MICROARRAY TECHNOLOGY CHALLENGES 86

FIGURE 18 DNA MICROARRAY COST-VOLUME CURVE 87

PROTEIN MICROARRAY TECHNOLOGIES 88

INTRODUCTION 88

FIGURE 19 IMPORTANCE OF PROTEINS 88

PROTEOMICS WORKFLOW 89

FIGURE 20 PROTEIN ANALYSIS APPROACHES CONTRASTED 89

PROTEIN MICROARRAY DESIGN FEATURES 90

TABLE 39 PROTEIN MICROARRAY PLATFORMS 90

PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS 91

TABLE 40 PROTEIN MICROARRAYS AS RESEARCH TOOLS 92

PROTEIN MICROARRAY TYPES 93

TABLE 41 PROTEIN MICROARRAY PRODUCT TYPES 93

Protein Microarray Types (Continued) 94

PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 95

TABLE 42 PROTEIN MICROARRAY TECHNICAL CHALLENGES 96

Protein Microarray Technology Challenges (Continued) 97

PROTEIN MICROARRAY TECHNOLOGY TRENDS 98

TABLE 43 PROTEIN MICROARRAY TECHNOLOGY TRENDS 98

EMERGING MICROARRAY TECHNOLOGIES 99

TABLE 44 EMERGING MICROARRAY TECHNOLOGIES 99

GLYCOMICS MICROARRAYS 100

Glycomics Microarrays (Continued) 101

TMAS 102

FCMS 103

TABLE 45 U.S. GOVERNMENT INITIATIVES PROMOTING EMERGING MICROARRAYS 104

MICROARRAY TECHNOLOGY TRENDS 105

TABLE 46 MICROARRAY TECHNOLOGY TRENDS 105

MICROARRAY TECHNOLOGY TRENDS (CONTINUED) 106

Chapter-5: LOAC TECHNOLOGIES

INTRODUCTION 107

TABLE 47 MICROFLUIDICS PRODUCT LIFE CYCLE STAGE 107

TABLE 48 LOAC SUBSTRATE TECHNOLOGIES 108

LOAC TYPES 109

TABLE 49 LOAC TYPES 109

IN VITRO PROTEOMICS 109

ELECTROPHORESIS ON A CHIP 110

STRUCTURAL PROTEOMICS 110

PCR ON A CHIP 111

IMMUNOASSAYS ON A CHIP 112

Immunoassays on a Chip (Continued) 113

TABLE 50 IMMUNOASSAY-ON-A-CHIP APPLICATIONS 114

LOAC APPLICATIONS 114

TABLE 51 LOAC MARKET SEGMENTS 115

TABLE 52 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 116

LOAC KEY TECHNOLOGY TRENDS 116

TABLE 53 LOAC KEY TECHNOLOGY TRENDS 117

TABLE 54 LOAC TECHNOLOGY PLATFORMS 118

LOAC TECHNOLOGY CHALLENGES 119

TABLE 55 LOAC TECHNOLOGY CHALLENGES 120

Chapter-6: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT

BIOCHIP MARKET SEGMENTATION 121

TABLE 56 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 121

DRUG DISCOVERY AND DEVELOPMENT 122

TABLE 57 DRUG R&D INVESTMENT BY STAGE, 2003 (%) 123

DRUG INDUSTRY CHALLENGES 123

OVERVIEW OF THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 124

FIGURE 21 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 124

TABLE 58 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 125

TABLE 58 (CONTINUED) 126

DRUG TARGET IDENTIFICATION 127

DRUG DISCOVERY 127

Structural Biology 127

Lead Generation 128

Lead Generation (Continued) 129

Lead Generation (Continued) 130

Lead Optimization 131

Process R&D 132

Preclinical and Clinical Trials 132

NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 132

TABLE 59 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 132

TABLE 59 (CONTINUED) 133

Needs in the Drug Discovery and … (Continued) 133

Needs in the Drug Discovery and … (Continued) 134

FIGURE 22 VALIDATION GAP FOR FUTURE DRUG TARGETS (NUMBER OF POTENTIAL DRUG TARGETS) 135

Needs in the Drug Discovery and … (Continued) 136

Chapter-7: BIOCHIP APPLICATIONS IN DIAGNOSTICS

INTRODUCTION 137

DRIVING FORCES FOR ADOPTION OF BIOCHIP DIAGNOSTIC PLATFORMS 137

BIOMARKER DISCOVERY AND VALIDATION 137

CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS 138

TABLE 60 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 139

MICROARRAY STANDARDIZATION EFFORTS 140

Microarray Quality Control Project 140

External RNA Controls Consortium (ERCC) Study 141

Association of Bimolecular Resource Facilities (ABRF) CGH Microarray Platform Study 142

TABLE 61 COMPARISON OF ARRAY-CGH PLATFORMS 142

OVERVIEW OF MDX 143

INTRODUCTION 143

BENEFITS OF BIOCHIPS AS AN MDX PLATFORM 144

Benefits of Biochips as an MDX Platform (Continued) 145

FIGURE 23 BIOCHIPS TARGET HIGH GROWTH, HIGH MARGIN PORTION OF THE IVD MARKET 146

TABLE 62 BIOTECHNOLOGY DRUGS APPROVED BY THE FDA, 1980–2008 (NUMBER) 147

PHARMACOGENOMICS TESTS 147

Pharmacogenomics Tests (Continued) 148

STRATEGIES FOR COMMERCIALIZING PGX TESTS 149

MDX MARKET PENETRATION CHALLENGES 150

TABLE 63 COMPARISON OF DNA-BASED MDX PLATFORMS 151

TABLE 64 FACTORS AFFECTING PENETRATION OF BIOCHIPS INTO THE MDX MARKET 152

MDX Market Penetration Challenges (Continued) 153

MDX MARKET SEGMENTS 154

MDX TEST SENSITIVITY AND SPECIFICITY 155

FIGURE 24 SENSITIVITY AND SPECIFICITY 156

STATUS OF BIOCHIPS DIAGNOSTICS BY INDICATION 157

SUMMARY OF BIOCHIPS DIAGNOSTICS 157

CANCER OVERVIEW 157

TABLE 65 U.S. INCIDENCE AND TREATMENT DECISIONS FOR SELECTED CANCERS, 2009 157

HEMATOLOGICAL CANCERS 158

BLADDER CANCER 158

BREAST CANCER 159

Breast Cancer Screening 159

Prognosis and Pharmacogenetics Tests 160

FIGURE 25 BREAST CANCER TREATMENT DECISION TREE FOR ONCOTYPE DX 161

TABLE 66 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 162

Breast Cancer MDx Platforms 162

TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS 163

Breast Cancer Multivariate Diagnostic Tests 164

TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE BREAST CANCER TESTS, BY PARAMETER 164

TABLE 68 (CONTINUED) 165

Breast Cancer Multivariate … (Continued) 166

Regulatory Status of Gene Profiling Diagnostic Tests 167

TABLE 69 FDA REGULATORY POSITION ON IVDMIA 167

CERVICAL CANCER 168

TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS 168

TABLE 70 (CONTINUED) 169

COLORECTAL CANCER 170

Conventional Colorectal Cancer Screening Tests 170

TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 171

Molecular Colorectal Cancer Diagnostics Tests 172

TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 172

Molecular Colorectal Cancer … (Continued) 173

CUP 174

TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS 175

GASTRIC CANCER 176

LUNG CANCER 177

Lung Cancer (Continued) 178

OVARIAN CANCER 179

TABLE 74 OVARIAN CANCER SCREENING TESTS 179

TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS 180

PANCREATIC CANCER 180

PEDIATRIC CANCERS 181

PROSTATE CANCER 181

Prostate Cancer (Continued) 182

COMPREHENSIVE CANCER TESTS 183

STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS 183

SEPSIS 183

TUBERCULOSIS 184

MRSA 184

INFLUENZA 185

OTHER INFECTIOUS DISEASES 185

STATUS OF BIOCHIP-BASED DME DIAGNOSTICS 186

DMES 186

TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS 186

DMEs (Continued) 187

WARFARIN DOSING 188

TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE 189

TABLE 77 (CONTINUED) 190

Warfarin Dosing (Continued) 191

TABLE 78 CYP450 GENE FAMILY PHARMACOGENETIC DIAGNOSTIC GLOBAL TEST MARKET POTENTIAL, 2009 ($ MILLIONS) 192

STATUS OF BIOCHIP-BASED NEUROLOGICAL DIAGNOSTICS 192

ALZHEIMERS DISEASE 192

SCHIZOPHRENIA 193

STATUS OF BIOCHIP-BASED HEART DISEASE DIAGNOSTICS 193

CHF FAILURE 193

TABLE 79 BNP MDX TESTS FOR CHF 194

CHF Failure (Continued) 195

OTHER CARDIAC DIAGNOSTICS 196

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR CF 197

TABLE 80 CF BIOCHIP DIAGNOSTIC PLATFORMS 197

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR PRE- AND POST-NATAL 198

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR IMMUNE DISEASES 199

HLA TYPING TESTS 199

AUTOIMMUNE TESTING 200

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR FOOD SAFETY/QC 201

TABLE 81 BIOCHIPS STATUS IN FOOD SAFETY/QC MARKET 201

STATUS OF BIOCHIP- … (CONTINUED) 202

Chapter-8: BIOCHIP MARKET GROWTH DRIVING FORCES

INTRODUCTION 203

FIGURE 26 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO MICROARRAYS AND LAB ON A CHIP, 2000–2009 (NUMBER OF PUBMED CITATIONS) 203

FIGURE 26 (CONTINUED) 204

BIOCHIP GROWTH DRIVING FORCES 204

TABLE 82 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 205

FUNDING FOR LIFE SCIENCE RESEARCH 205

TABLE 83 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, 2009 ($ MILLIONS) 206

FIGURE 27 NIH ANNUAL FUNDING BUDGET, 2000–2009 ($ BILLIONS) 206

LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES 207

TABLE 84 RESEARCH INITIATIVES DRIVING BIOCHIP GROWTH, 1999–2008 208

Large-scale Genomic, Proteomic, … (continued) 209

NEED FOR MORE EFFICIENT DRUG DISCOVERY AND DEVELOPMENT PROCESS 210

GROWTH IN PERSONALIZED MEDICINE 210

NEED FOR EARLY DETECTION OF CANCERS 211

AGING POPULATIONS 211

NEW DISCOVERIES IN GENOMICS AND PROTEOMICS 212

MINIATURIZATION OF BIOCHIPS 212

DECLINE IN GENETIC ANALYSIS COSTS 212

DISCOVERY OF GENE- AND SNP-DISEASE ASSOCIATIONS 213

Chapter-9: BIOCHIP MARKETS

GLOBAL BIOCHIP MARKET 214

TABLE 85 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 214

TABLE 86 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 215

MICROARRAY MARKETS 216

TABLE 87 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH 2014 ($ MILLIONS) 216

DNA MICROARRAY MARKETS 217

DNA MICROARRAY MARKET BY APPLICATION 217

TABLE 88 GLOBAL VALUE OF DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 217

DNA Microarray Market by Application (Continued) 218

FIGURE 28 ENTRIES TO MIRNA DATABASE, 2002–2009 (NUMBER) 219

TABLE 89 GLOBAL VALUE OF GENOTYPING DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 220

DNA MICROARRAY MARKET BY END-USE INDUSTRY 220

TABLE 90 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 221

DNA MICROARRAY MARKET BY FORMAT 222

TABLE 91 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT, THROUGH 2014 ($ MILLIONS) 222

BIOCHIPS DIAGNOSTICS MARKETS 223

BIOCHIPS DIAGNOSTIC MARKET BY APPLICATION 223

TABLE 92 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 224

Biochips Diagnostic Market by Application (Continued) 225

BIOCHIP DIAGNOSTICS MARKET BY BIOCHIP TYPE 226

TABLE 93 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 226

CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION 227

TABLE 94 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY INDICATION, THROUGH 2014 ($ MILLIONS) 227

Cancer Diagnostics Biochips Market … (Continued) 228

CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE 229

TABLE 95 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 229

TABLE 96 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 230

DIAGNOSTIC DNA MICROARRAYS MARKET BY ANALYSIS METHOD 231

TABLE 97 GLOBAL VALUE OF DIAGNOSTIC DNA MICROARRAYS BY ANALYSIS METHOD, THROUGH 2014 ($ MILLIONS) 231

Diagnostic DNA Microarrays Market … (Continued) 232

DIAGNOSTIC DNA MICROARRAYS MARKET BY DIAGNOSTIC FUNCTION 233

TABLE 98 GLOBAL VALUE OF DNA MICROARRAYS DIAGNOSTICS BY DIAGNOSTIC FUNCTION, THROUGH 2014 ($ MILLIONS) 233

DIAGNOSTIC PROTEIN MICROARRAY MARKET BY TECHNOLOGY 234

TABLE 99 GLOBAL VALUE OF PROTEIN MICROARRAY DIAGNOSTICS MARKET BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 235

PROTEIN MICROARRAYS MARKETS 236

PROTEIN MICROARRAYS MARKETS BY TECHNOLOGY 236

TABLE 100 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 236

Protein Microarrays Markets by Technology (Continued) 237

PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT 238

TABLE 101 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT, THROUGH 2014 ($ MILLIONS) 238

TABLE 102 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 239

PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY 240

TABLE 103 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 240

EMERGING MICROARRAYS MARKETS 241

EMERGING MICROARRAYS MARKET BY TECHNOLOGY 241

TABLE 104 GLOBAL VALUE OF EMERGING MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 241

EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY 242

TABLE 105 GLOBAL VALUE OF EMERGING MICROARRAYS BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 243

LOAC MARKETS 243

VALUE OF LOAC DEVICES BY END-USE INDUSTRY 243

TABLE 106 GLOBAL VALUE OF LOAC DEVICES BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 244

Value of LOAC Devices by End-Use Industry (Continued) 245

Value of LOAC Devices by End-Use Industry (Continued) 246

Value of LOAC Devices by End-Use Industry (Continued) 247

LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION 248

TABLE 107 GLOBAL VALUE OF LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 249

LOAC Drug Discovery and Development … (Continued) 250

LOAC DIAGNOSTICS MARKET BY APPLICATION 251

TABLE 108 GLOBAL VALUE OF LOAC DEVICES DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 252

LOAC Diagnostics Market by Application (Continued) 253

BIOCHIPS GEOGRAPHIC MARKETS 254

GLOBAL VALUE OF BIOCHIPS PRODUCTS BY GEOGRAPHY 254

TABLE 109 GLOBAL VALUE OF BIOCHIP PRODUCTS BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 255

MICROARRAY GEOGRAPHICAL MARKETS 255

TABLE 110 GLOBAL VALUE OF DNA MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 256

TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257

TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257

LOAC GEOGRAPHICAL MARKETS 258

TABLE 113 GLOBAL VALUE OF LOAC BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 258

Chapter-10: INDUSTRY DYNAMICS

INTRODUCTION 259

RECENT ACQUISITIONS IN THE BIOCHIP INDUSTRY 259

TABLE 114 KEY ACQUISITIONS IN BIOCHIP INDUSTRY, 2007–2009 260

RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 261

RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 262

RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 263

DNA MICROARRAYS COMPETITIVE LANDSCAPE 264

TABLE 115 LEADING DNA MICROARRAY SUPPLIERS 264

TABLE 115 (CONTINUED) 265


'/>"/>
SOURCE S OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265
Copyright©2010 PR Newswire.
All rights reserved


Related biology news :

1. Reportlinker Adds Biometrics: Technologies and Global Markets
2. Reportlinker Adds Enzymes in Drug Manufacturing
3. Reportlinker Adds Bioinformatics - A Global Market Overview
4. Reportlinker Adds Global Biometric Forecast to 2012
5. Reportlinker Adds Global Bioinformatics Industry
6. Reportlinker Adds Indian Biometric Market
7. Reportlinker Adds Biometrics: Technologies and Global Markets
8. Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip
9. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
10. Reportlinker Adds Global Flow Cytometers Industry
11. Reportlinker Adds World Biometrics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... Thailand (PRWEB) , ... May 25, 2016 , ... ... participation of a Thai delegation at BIO 2016 in San Francisco. Located at ... sector will be available to answer questions and discuss the Thai biotechnology and ...
(Date:5/25/2016)... AZ (PRWEB) , ... May 25, 2016 , ... ... Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of the ... 2015. Dr. Fitzmaurice is no stranger to going above and beyond in his ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since the ... in her left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen ... to repair her cruciate ligament and help with the pain of Lady’s arthritis. Dr ...
Breaking Biology Technology: